Abstracts tagged "cytokines"

Abstract Number: 1449 • ACR Convergence 2020
Altered Splicing in Leukocytes from Patients with Antiphospholipid Syndrome, Systemic Lupus Erythematosus and Antiphospholipid Syndrome with Lupus: Clinical Involvement
Alejandra Maria Patiño-Trives¹, Alejandro Ibáñez-Costa², Carlos Pérez-Sánchez¹, Laura Pérez-Sanchez³, Maria Luque-Tevar¹, Iván Arias de la Rosa¹, María-Carmen Abalos-Aguilera¹, Desirée Ruiz-Vilchez⁴, Pedro Segui⁵, Mario Espinosa⁵, Nuria Barbarroja¹, Eduardo Collantes⁴, Justo P. Castaño⁵, Raul M Luque⁵, María de los ángeles Aguirre-Zamorano⁵ and Chary Lopez-Pedrera¹, ¹Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Cordoba, Spain, ²IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, ³Hospital Universitario Reina Sofía, Córdoba, Spain, ⁴Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Córdoba, Spain, ⁵IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba
Background/Purpose: To identify shared and differential changes in the splicing machinery of immune cells from antiphospholipid syndrome (APS), systemic lupus erythematosus (SLE) and antiphospholipid syndrome…
Abstract Number: 0777 • ACR Convergence 2020
CLEC12A Expression as a Potential Predictor of Disease Activity in Early Rheumatoid Arthritis
Myriam Vaillancourt¹, Philippe Desaulniers¹, Guillaume Paré¹, Nathalie Pagé¹, Asmaa Lachaab¹, Anthony Kerever¹, Anne-Sophie Julien¹, Nathalie Amiable¹, Martin Pelletier¹, Philippe Tessier¹, Louis Bessette², Paul Fortin³, Laetitia Michou¹ and Maria Fernandes¹, ¹Université Laval, Québec, QC, Canada, ²Laval University, Quebec, Canada, ³CHU de Quebec - Universite Laval, Quebec, Canada
Background/Purpose: Rheumatoid arthritis (RA) develops as a result of the dysregulation of immune activating and inhibitory pathways. Several lines of evidence indicate that inhibitory receptors…
Abstract Number: 1484 • ACR Convergence 2020
Efficacy of Tocilizumab in Patients with Hand Osteoarthritis: Double Blind, Randomized, Placebo Controlled, Multicenter Trial
Pascal Richette¹, Augustin Latourte², Jeremie Sellam³, Daniel Wendling⁴, Muriel Piperno⁵, Philippe Goupille⁶, Yves-Marie Pers⁷, Florent Eymard⁸, Sebastien Ottaviani⁹, Paul Ornetti¹⁰, Rene-Marc Flipo¹¹, Bruno Fautrel¹², Jean-Pierre Bertola¹³, Eric Vicaut¹⁴ and Xavier Chevalier¹⁵, ¹Department of Rheumatology, Lariboisière Hospital, AP-HP Université de Paris, INSERM U1132, Paris, ²Department of Rheumatology, Lariboisière Hospital, AP-HP Université de Paris, INSERM U1132, Paris, France, ³AP-HP, Hôpital Saint-Antoine, Service de Rhumatologie, Centre de Recherche Saint-Antoine, INSERM UMR_S 938,Sorbonne Université, Paris, 75012, France, Paris, France, ⁴CHU Besançon, department of rheumatology, Besancon, France, ⁵Rheumatology Department, Lyon University Hospital, Lyon, France, ⁶CHU Tours, department of rheumatology, Tours, France, ⁷IRMB, University of Montpellier, Inserm U1183, University Hospital of Montpellier, Montpellier, France, ⁸APHP Henri Mondor Hospital, Creteil, France, ⁹Rheumatology Department, Bichat hospital, APHP, Paris, France, ¹⁰CHU Dijon, INSERM CAPS 1093, plateforme d’investigation technologique CIC1432, Dijon, France, ¹¹Lille University Hospital, Lille, France, ¹²Sorbonne University, INSERM, IPLES; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France, ¹³CHUGAI PHARMA FRANCE, Paris, France, ¹⁴Clinical Research Unit, Paris, ¹⁵AP-HP, UPEC, Créteil
Background/Purpose: To evaluate the efficacy of tocilizumab, an antibody against interleukin-6 receptor (IL-6R), in patients with hand osteoarthritis.Methods: This was a multicenter, 12-week, randomized, double-blind,…
Abstract Number: 0003 • ACR Convergence 2020
Assessing Cytokine Profiles and COVID Serology in Patients on Immunosuppression to Guide Care Recommendations
Quinn Pritchett¹, Rebecca Overbury¹, Dorota Lebiedz-Odrobina¹, Julie Thomas¹, Tawnie Braaten², Stacey Clardy¹, Marc Elgort³, Emily Spivak¹, Patricia Slev³, Lisa Peterson³ and Tracy Frech⁴, ¹University of Utah, Salt Lake City, UT, ²University of Utah, Salt Lake City, ³ARUP, Salt Lake City, UT, ⁴University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT
Background/Purpose: The COVID-19 pandemic is especially terrifying for patients on immunosuppression for autoimmune disease. With the exception of social isolation, experts do not have clear…
Abstract Number: 0791 • ACR Convergence 2020
Peficitinib Inhibits Angiogenesis via Suppression of VEGF Production in Rheumatoid Arthritis Fibroblast-like Synoviocytes
Yuzo Ikari¹, Takeo Isozaki¹, Kuninobu Wakabayashi¹ and Tsuyoshi Kasama², ¹Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Koutou-ku Tokyo, Japan
Background/Purpose: Peficitinib is a novel Janus kinase (JAK) inhibitor developed for the treatment of rheumatoid arthritis (RA). Peficitinib has approved in 2019 in Japan, but…
Abstract Number: 1511 • ACR Convergence 2020
Clinical Features and Select Dysregulated Immune Parameters Distinguish Blood Relatives Who Remain Clinically Stable or Progress to Incomplete Lupus or Classified SLE in the Lupus Autoimmunity in Relatives (LAUREL) Follow-up Cohort
Melissa Munroe¹, Kendra Young², Jill Norris³, Joel Guthridge⁴, Diane Kamen⁵, Timothy Niewold⁶, Gary Gilkeson⁷, Michael Weisman⁸, Mariko Ishimori⁹, Daniel Wallace¹⁰, David Karp¹¹, John Harley¹² and Judith James¹³, ¹Oklahoma Medical Research Foundation/Progentec Diagnostics, Inc., Oklahoma City, OK, ²University of Colorado Denver, Aurora, CO, ³Colorado School of Public Health, Aurora, CO, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Medical University of South Carolina, Charleston, SC, ⁶NYU School of Medicine, New York, NY, ⁷Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁸Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, LOS ANGELES, CA, ⁹Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Cedars-Sinai Medical Center/UCLA, Los Angeles, CA, ¹¹UT Southwestern Medical Center, Dallas, TX, ¹²Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Cincinnati, OH, ¹³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK
Background/Purpose: Identifying populations at risk of SLE is essential to curtail inflammatory damage and identify individuals for prevention trials. Unaffected blood relatives (BRs) of lupus…
Abstract Number: 0065 • ACR Convergence 2020
The Energy-dependent Hierarchy of Immune Functions in Human Monocytes
Pierre-Louis Krauß¹, Thomas Buttgereit², Yuling Chen¹, Moritz Pfeiffenberger¹, Timo Gaber¹ and Frank Buttgereit³, ¹Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Rheumatology and Clinical Immunology, Berlin, Germany, ²Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Dermatology, Venerology, and Allergology, Berlin, Germany, ³Charité University Medicine, Berlin, Germany
Background/Purpose: At sites of inflammation, monocytes carry out specific immunological functions while facing challenging bioenergetic restrictions. Here, we investigated the potential of human monocytes to…
Abstract Number: 0851 • ACR Convergence 2020
Iberdomide Decreases B Cells and Plasmacytoid Dendritic Cells, Increases Regulatory T Cells and IL-2, and Has Enhanced Clinical Efficacy in Active Systemic Lupus Erythematosus Patients with High Aiolos or the IFN Gene Expression Signature
Peter Lipsky¹, Ronald van Vollenhoven², Thomas Dörner³, Victoria Werth⁴, Joan Merrill⁵, Richard Furie⁶, Milan Petronijevic⁷, Benito Velasco Zamora⁸, Maria Majdan⁹, Fedra Irazoque-Palazuelos¹⁰, Robert Terbrueggen¹¹, Nikolay Delev¹², Michael Weiswasser¹², Shimon Korish¹², Nataliya Agafonova¹², Mark Stern¹³, Sarah Hersey¹³, Ying Ye¹³, Allison Gaudy¹², Zhaohui Liu¹², Shaojun Tang¹³ and Peter Schafer¹², ¹RILITE Foundation, Charlottesville, VA, ²Amsterdam University Medical Centers, Amsterdam, Netherlands, ³DRFZ and Charité University Hospitals, Berlin, Germany, ⁴University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁷Military Medical Academy, Belgrade, Serbia, ⁸Instituto CER S.A., Buenos Aires, Argentina, ⁹Medical University of Lublin and Samodzielny Publicnzy Szpital Kliniczny Nr 4 w Lublinie, Lublin, Poland, ¹⁰Centro de Investigación y Tratamiento Reumatológico S.C, Miguel Hidalgo, Mexico, ¹¹DxTerity Diagnostics Inc, Rancho Dominguez, ¹²Bristol Myers Squibb, Princeton, ¹³Bristol-Myers Squibb, Princeton
Background/Purpose: Iberdomide is a high-affinity cereblon ligand that promotes ubiquitination and proteasomal degradation of Ikaros (IKZF1) and Aiolos (IKZF3), transcription factors linked to the genetic…
Abstract Number: 1523 • ACR Convergence 2020
Pulmonary Cytokine, Chemokine and Growth Factor Profiles of Distinct Radiographic Patterns of Interstitial Lung Disease in Systemic Sclerosis
Elizabeth Volkmann¹, Donald Tashkin², Ning Li², Mei Leng², Grace Kim², Jonathan Goldin², Airi Harui² and Michael Roth², ¹University of California, Los Angeles, Los Angeles, CA, ²University of California, Los Angeles, Los Angeles
Background/Purpose: The radiological hallmarks of systemic sclerosis-related interstitial lung disease (SSc-ILD) include interstitial inflammation (ground glass opacity) with reticular changes (fibrosis). The precise pathobiology of…
Abstract Number: 0095 • ACR Convergence 2020
Systematic Evaluation of Nine Monogenic Autoinflammatory Diseases Reveals Common and Disease-Specific Correlations with Allergy-Associated Features
Moses Kitakule¹, Brian Dizon², Cristhian Gutierrez-Huerta¹, Sarah Blackstone², Aarohan Burma¹, Aran Son¹, Natalie Deuitch¹, Sofia Rosenzweig¹, Hirsh Komarow¹, Deborah Stone³, Anne Jones⁴, Michele Nehrbecky¹, Patrycja Hoffmann⁵, Tina Romeo⁶, Adriana de Jesus⁷, Sara Alehashemi⁸, Megha Garg⁹, Sofia Torreggiani¹⁰, Gina Montealegre Sanchez¹¹, Katelin R. Honer¹⁰, Karyl Barron¹, Ivona Aksentijevich⁴, Amanda Ombrello¹², Raphaela Goldbach-Mansky¹³, Daniel Kastner¹⁴, Joshua Milner¹⁵, Pamela Frischmeyer-Guerrerio¹ and Daniella Schwartz¹⁶, ¹National Institutes of Health, Bethesda, ²National Institutes of Health, BETHESDA, MD, ³NIH, Bethesda, ⁴National Human Genome Research Institute, Bethesda, MD, ⁵NIH, Vienna, VA, ⁶NIH, Bethesda, MD, ⁷Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Silver Spring, MD, ⁸Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Clarksville, MD, ⁹NIH/NIAID, Rochester, NY, ¹⁰Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Bethesda, MD, ¹¹NIAID/NIH, Rockville, MD, ¹²National Human Genome Research Institute/National Institutes of Health, Bethesda, MD, ¹³Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Potomac, MD, ¹⁴National Human Genome Research Institute (NHGRI), NIH, Bethesda, MD, ¹⁵Division of Allergy, Immunology and Rheumatology Columbia University Medical Center, New York, NY, ¹⁶National Institutes of Health Clinical Center, Bethesda, MD
Background/Purpose: Monogenic autoinflammatory diseases (AID) are caused by mutations in innate immune signaling genes. The effect of these mutations on the risk of allergy is…
Abstract Number: 0990 • ACR Convergence 2020
Interferon Lambda Promotes Human Plasma Cell Differentiation in Lupus and Healthy Donors
Jennifer Barnas¹, Jennifer Albrecht¹ and Jennifer Anolik¹, ¹University of Rochester Medical Center, Rochester, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by antinuclear autoantibodies produced by plasma cells. Type I interferon (IFN) are cytokines which…
Abstract Number: 1529 • ACR Convergence 2020
Differentially Expressed Chemokines and Cytokines in Peripheral Blood Mononuclear Cells (PBMCs) of Rheumatoid Arthritis (RA) Patients
Noha Elemam¹, Mahmood Hachim², Suad Hannawi³ and Azzam Maghazachi⁴, ¹University of Sharjah, Sharjah, United Arab Emirates, ²Mohammed Bin Rashid University Of Medicine and Health Sciences, Dubai, ³Ministry of Health and Prevention, Dubai, United Arab Emirates, ⁴University of Sharjah, Sharjah
Background/Purpose: Rheumatoid arthritis (RA) is the most prevalent autoimmune disease, where various immune cells are associated such as monocytes, natural killer (NK) cells, B cells,…
Abstract Number: 0172 • ACR Convergence 2020
Early Treatment and IL1RN Single Nucleotide Polymorphisms Affect Response to Anakinra in Systemic Juvenile Idiopathic Arthritis
Marianna Nicoletta Rossi¹, Manuela Pardeo², Denise Pires Marafon², Emanuela Sacco², Chiara Passarelli³, Claudia Bracaglia², Chiara Perrone³, Anna Tulone⁴, Giusi Prencipe⁵ and Fabrizio De Benedetti⁶, ¹Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Lazio, Italy, ²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ³U.O.C. Laboratory of Medical Genetics, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ⁴Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ⁵Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, ⁶Division of Rheumatology, Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) represents 10-20% of all chronic arthritis during childhood. The interleukin 1 (IL-1) play a pivotal role in the pathogenesis…
Abstract Number: 0994 • ACR Convergence 2020
Does Tofacitinib Impact B Cell Functions?
Guillaume Decarriere¹, Julie Mielle², Bernard Combe³, Jacques Morel¹, Rachel Audo² and Claire Daien¹, ¹Rheumatology department, CHU Montpellier and University of Montpellier, Montpellier, France, ²Institut de génétique moléculaire de Montpellier (IGMM), Montpellier, France, ³University of Montpellier, Montpellier, France
Background/Purpose: Tofacitinib (tofa) inhibits cytokine signaling mediated by JAK1 JAK3 pathways leading therefore to a decrease in Th17 and an increase of Treg cells. The…
Abstract Number: 1531 • ACR Convergence 2020
Characterization of Cytokine/chemokine Profile in Patient-derived M1/ M2 Macrophages to Identify Biomarkers for Genetically-defined Systemic Autoinflammatory Diseases
Farzana Bhuyan¹, Adriana Almeida de Jesus², Kim Johnson³, Jacob Mitchell⁴, Yan Huang⁵ and Raphaela Goldbach-Mansky⁵, ¹NIH, bhetesda, MD, ²Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Bethesda, ³NIH, NIAID, Bethesda, ⁴Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Bethesda, MD, ⁵NIH, Bethesda
Background/Purpose: Genetic mutations in key regulatory molecules of the innate immune system cause autoinflammatory diseases through propagation of hyperinflammatory responses. Monocytes/ macrophages regulate inflammatory processes…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].